US Market News
1月前
DarioHealth Reports First Quarter 2026 Financial and Operating ResultsMay 13, 2026 6:30 AM
PR Newswire (US) First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growthOperating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarterOperating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarterChannel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered livesNow in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks in the northeastern U.S. as a day-one anchor account10 new accounts added during the first quarter ended March 31, 2026 — all outside the normal benefit cycle; Approximately $127 million pipeline across 241 active potential opportunitiesNEW YORK, May 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the first quarter ended March 31, 2026. "The first quarter of 2026 was our second consecutive quarter of sequential revenue growth, alongside continued reductions in operating expenses. Our channel partner ecosystem now provides access to more than 116 million covered lives through blue-chip partners such as Solera and Amwell. These relationships are expanding our reach into leading national and regional payer organizations across the U.S., while strengthening our ability to scale through trusted, established market access channels," said Erez Raphael, Dario's Chief Executive Officer."In a strategic move, we are also moving closer to care, backed by more than 100 peer-reviewed clinical studies, which we believe expands both our role and our revenue model into claims-based and outcomes-driven payments. This move broadens our platform toward clinical gap closure and care delivery, with the potential of positioning Dario across a larger share of the healthcare workflow and associated spend, while continuing to grow our subscription-based annual recurring revenue contracts," Raphael added.Underpinning this strategy, DarioIQ™ — Dario's proprietary artificial intelligence ("AI") layer, operating on 13 billion real-world data points generated through U.S. Food and Drug Administration-cleared connected devices — continued to show meaningful performance during the first quarter of 2026, with behavior-triggered engagement programs now delivering up to a 40% improvement in member retention and up to a 57% lift in active sessions versus control. The combination of proprietary data, a regulated device-to-data pipeline, and a continuously learning AI layer represents a competitive moat that is difficult to replicate.Steven Nelson, Dario's President and Chief Commercial Officer, commented, "Our channel-led commercial model is producing the compounding effect we built it for. With 10 new accounts all off cycle already added in the first quarter of 2026 and several large, contracted enterprise implementations coming in the second half of the year, we believe that we are reaching the phase where our 2025 sales execution translates into meaningful scale."First Quarter 2026 Financial HighlightsRevenue of $5.6 million, increased from $5.2 million in the fourth quarter of 2025 — the second consecutive quarter of sequential growthGAAP gross margin of 57%; Non-GAAP business-to-business-to-consumer ("B2B2C") gross margin of approximately 80% for the ninth consecutive quarterOperating expenses of $10.5 million, decreased by 21% year-over-year and decreased by 8% sequentially; operating loss of $7.3 million, decreased by 22% year-over-year and decreased by 15% sequentiallyCash and short-term deposits of $20 million; net cash used in operations of $6 million, decreased by 10% year-over-year."We delivered a second consecutive quarter of sequential revenue growth with sustained B2B2C gross margins, while further reducing operating expenses. With our cash position and continued cost discipline, we believe that we are well positioned to expand our operating leverage," said Chen Franco Yehuda, Dario's Chief Financial Officer.Financial Results for the Three Months Ended March 31, 2026Revenue for the three months ended March 31, 2026 was $5.6 million, compared to $6.8 million, for the three months ended March 31, 2025, and $5.2 million for the three months ended December 31, 2025. The year-over-year decrease was primarily attributable to the non-recurrence of $1.3 million in revenues from a pharmaceutical customer recognized in the prior-year period before Dario transitioned away from one-time and non-recurring revenues to its focus on building annual recurring revenues from its core B2B2C business. The decline was partially offset by growth in channel partner revenues — including increased contributions from Solera — and continued expansion in direct to consumer musculoskeletal ("MSK") product sales. On a sequential basis, revenues increased by 6.7% from the fourth quarter of 2025, driven by onboarding of new clients coming from channel partners and increased sales of MSK product, marking the second consecutive quarter of quarter-over-quarter revenue growth.Gross profit for the three months ended March 31, 2026 was $3.2 million, compared to gross profit of $3.9 million for the three months ended March 31, 2025, and gross profit of $2.8 million for the three months ended December 31, 2025. Gross margin remained substantially stable year-over-year, resulting mainly from the change in revenue, offset by lower amortization of technology expenses recorded in the cost of revenues. On a sequential basis, gross margin improved from the fourth quarter of 2025, driven mainly by higher revenues and lower hosting and server expenses. Gross profit as a percentage of revenue was 57% in the three months ended March 31, 2026, compared to 58% in the three months ended March 31, 2025, and up from 54% in the three months ended December 31, 2025.Non-GAAP gross profit, excluding $0.2 million of amortization, stock-based compensation and depreciation, was $3.4 million, or 61% of revenues, for the three months ended March 31, 2026, compared to non-GAAP gross profit of $4.8 million, or 71% of revenues, for the three months ended March 31, 2025, and non-GAAP gross profit of $3.0 million, or 57% of revenues, for the three months ended December 31, 2025.Total operating expenses for the three months ended March 31, 2026, were $10.5 million compared to $13.3 million for the three months ended March 31, 2025, and $11.4 million for the three months ended December 31, 2025, representing a decrease of $2.8 million, or 21%, compared to the three months ended March 31, 2025, and a decrease of $0.9 million, or 8%, compared to the three months ended December 31, 2025. The year-over-year and sequential decrease in operating expenses resulted mainly from increased operational efficiency.Non-GAAP operating expenses (excluding stock-based compensation, depreciation and amortization expenses) for the three months ended March 31, 2026, were $8.7 million compared to $10.6 million for the three months ended March 31, 2025, and $9.0 million for the three months ended December 31, 2025, representing a decrease of 18% and 3%, respectively.Operating loss for the three months ended March 31, 2026 was $7.3 million, a decrease of $2.1 million, or 22%, compared to $9.4 million for the three months ended March 31, 2025, and a decrease of $1.3 million or 15% from $8.6 million for the three months ended December 31, 2025. The decrease in operating loss year-over-year and quarter-over-quarter was mainly due to an increase in operational efficiencies and post-merger integration activities.Non-GAAP operating loss (excluding stock-based compensation, and depreciation and amortization) for the three months ended March 31, 2026 was $5.3 million, representing an 8% decrease compared to a Non-GAAP operating loss of $5.8 million for the three months ended March 31, 2025, and 11% compared to a Non-GAAP operating loss of $6.0 million for the three months ended December 31, 2025.Net loss was $8.2 million for the three months ended March 31, 2026, a decrease of $1 million or 11% compared to a net loss of $9.2 million for the three months ended March 31, 2025, and a decline of $0.8 million or 9% from $9.0 million for three months ended December 31, 2025. Net loss decreased year-over-year and quarter-over-quarter due to lower operating expenses, partially offset by financial income that related to the revaluation of warrants.Non-GAAP net loss (excluding stock-based compensation, depreciation and amortization expenses) for the three months ended March 31, 2026 increased by 12% to $6.3 million compared to a non-GAAP net loss of $5.6 million for the three months ended March 31, 2025, and decreased by 3% quarter-over-quarter from a Non-GAAP net loss of $6.5 million in the three months ended December 31, 2025.A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures." Conference Call DetailsDate: Wednesday, May 13th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)Call me™: https://emportal.ink/4seOwJKParticipants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1756269&tp_key=7306dc53e7Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Wednesday, May 27th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1111468.About DarioHealth Corp. (NASDAQ: DRIO)DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses expectations regarding recurring revenue contribution from agreements signed in 2025, potential future growth trajectory and scaling opportunities, the expected expansion of channel partner reach and covered lives, the potential addition of a major northeastern U.S. hospital network as an anchor account, expectations regarding the conversion of pipeline opportunities into revenue, expectations for continued sequential revenue growth, the belief that DarioIQ™ engagement programs may improve member retention and active sessions, expectations regarding expansion into claims-based and outcomes-driven payment models, expectations regarding continued growth in subscription-based annual recurring revenue contracts, the belief that channel-led commercial strategy may drive increased scale and operating leverage, and the belief that it is well positioned to expand its operating leverage due to its cash position and continued cost discipline. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.Non-GAAP Financial MeasuresThis release includes financial measures that are not prepared in accordance with U.S. GAAP. Management uses these non-GAAP measures internally to evaluate ongoing operating performance and believes they provide investors with additional insight when used as a supplement to GAAP measures. Non-GAAP measures should not be considered in isolation from, or as a substitute for, GAAP measures. A reconciliation of GAAP to non-GAAP measures is provided in the financial tables included in this release.Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition-related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, depreciation and impairment expense, amortization of acquired technology and brand, financial (income) expenses, net, income tax, and acquisition costs. We believe these measures provide useful information to management and investors for analysis of our operating results.DarioHealth Corporate Contact
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.comDarioHealth Investor Relations Contact
Michael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310 DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (except stock and per share data)
March 31,
December 31,
2026
2025ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$14,977
$21,803Short-term bank deposits
5,035
4,214Short-term restricted bank deposits
252
229Trade receivables, net
2,219
2,144Inventories
4,172
4,316Other accounts receivable and prepaid expenses
2,079
2,361
Total current assets
28,734
35,067
NON-CURRENT ASSETS:
Deposits
80
80Operating lease right of use assets
607
717Long-term assets
454
304Property and equipment, net
511
549Intangible assets, net
15,468
15,931Goodwill
57,427
57,427
Total non-current assets
74,547
75,008
Total assets
$103,281
$110,075 The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (except stock and per share data)
March 31,
December 31,
2026
2025LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables
$3,468
$2,928Deferred revenues
501
714Operating lease liabilities
378
430Other accounts payable and accrued expenses
5,010
5,251
Total current liabilities
9,357
9,323
NON-CURRENT LIABILITIES
Operating lease liabilities
507
571Long-term loan
30,931
30,747Warrant liability
23
1,466Other long-term liabilities
83
46
Total non-current liabilities
31,544
32,830
STOCKHOLDERS' EQUITY **
Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued
and outstanding: 7,299,026 and 6,905,948 shares on March 31, 2026 and
December 31, 2025, respectively
4
4Additional paid-in capital
522,703
519,996Accumulated deficit
(460,327)
(452,078)
Total stockholders' equity
62,380
67,922
Total liabilities and stockholders' equity
$103,281
$110,075 The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands (except stock and per share data)
Three months ended
March 31,
2026
2025Revenues:
Services
$2,826
$4,875Consumer hardware
2,758
1,877Total revenues
5,584
6,752
Cost of revenues:
Services
563
865Consumer hardware
1,644
1,130Amortization of acquired intangible assets
177
875Total cost of revenues
2,384
2,870
Gross profit
3,200
3,882
Operating expenses:
Research and development
$2,385
$4,108Sales and marketing
4,898
5,873General and administrative
3,226
3,310
Total operating expenses
10,509
13,291
Operating loss
7,309
9,409
Interest expenses
1,149
—Other financial income, net
(266)
(204)
Total financial expenses (income), net
883
(204)
Loss before taxes
8,192
9,205
Income tax (benefit)
57
22
Net loss
$8,249
$9,227
Deemed dividend
$—
$4,839
Net loss attributable to common shareholders
$8,249
$14,066
Net loss per share:
Basic and diluted loss per share of common stock
$1.25
$2.87Weighted average number of common stock used in computing basic and
diluted net loss per share**
6,582,297
2,368,516 DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSU.S. dollars in thousands
Three months ended
March 31,
2026
2025Cash flows from operating activities:
Net loss
$(8,249)
$(9,227)Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation
1,441
2,342Change in operating lease right of use assets
110
110Amortization of acquired intangible assets
463
1,162Depreciation and impairment
61
94Change in fair value of warrant liability
(177)
(1,115)Accrued interest on short term bank deposits
(21)
—Non-cash financial expenses
159
293Changes in operating assets and liabilities:
Decrease (increase) in trade receivables, net
(75)
1,597Decrease (increase) in other accounts receivable, prepaid expense and long-term assets
269
(369)Decrease in inventories
144
130Increase (decrease) in trade payables
535
(300)Decrease in other accounts payable and accrued expenses
(341)
(1,666)Decrease in deferred revenues
(213)
(278)Decrease in operating lease liabilities
(116)
(126)Other
(15)
680
Net cash used in operating activities
(6,025)
(6,673)
Cash flows from investing activities:
Investment in short term bank deposit
(5,000)
—Proceeds from maturity of short-term bank deposit
4,200
—Purchase of property and equipment
(31)
(31)Disposals of property and equipment
5
—
Net cash used in investing activities
(826)
(31)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, net of issuance costs
—
6,815
Net cash provided by financing activities
—
6,815
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents
(6,851)
111Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash
equivalents
25
(21)Cash, cash equivalents and restricted cash and cash equivalents at beginning of period
21,803
27,764Cash, cash equivalents and restricted cash and cash equivalents at end of period
$14,977
$27,854Supplemental disclosure of cash flow information:
Cash paid during the period for interest on long-term loan
$965
$937Non-cash activities:
Exercise of pre-funded warrants to common stock
$1,266
$1,750Deferred cost related to ATM offering
$137
$—Purchase of property and equipment on credit
$5
$— Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended March 31, 2026
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$2,384
(5)
(180)
2,199Gross Profit
3,200
5
180
3,385
Research and development
2,385
(92)
(32)
2,261Sales and Marketing
4,898
(133)
(299)
4,466General and Administrative
3,226
(1,211)
(13)
2,002Total Operating Expenses
10,509
(1,436)
(351)
8,722Operating Loss$(7,309)
1,441
524
(5,344)Financing expenses
883
-
-
883Income Tax
57
57Net Loss$(8,249)
1,441
524
(6,284) Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended March 31, 2025
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$2,870
(10)
(890)
1,970Gross Profit
3,882
10
890
4,782
Research and development
4,108
(526)
(40)
3,542Sales and Marketing
5,873
(815)
(311)
4,747General and Administrative
3,310
(991)
(15)
2,304Total Operating Expenses
13,291
(2,332)
(366)
10,593Operating Loss$(9,409)
2,342
1,256
(5,811)Financing expenses
(204)
-
-
(204)Income Tax
22
22Net Loss$(9,227)
2,342
1,256
(5,629) Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-first-quarter-2026-financial-and-operating-results-302770792.htmlSOURCE DarioHealth Corp. Original: DarioHealth Reports First Quarter 2026 Financial and Operating Results
US Market News
3月前
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMarch 19, 2026 6:30 AM
PR Newswire (US)
Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-GAAP gross margins have sustained at 80% for 2 years on the core B2B2C business Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by 28% year-over-year, from $12.4 million to $9.0 million, leading to continued improvements in operating loss for the fourth quarter and full yearPipeline of commercial opportunities grew to $122 million as of December 31 2025, based on 200+ opportunities that are B2B2C Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with 36% growth in the fourth quarter of 2025 and continued expansion expected in international marketsDario will host an investor conference call and webcast at 8:30 a.m. ET todayNEW YORK, March 19, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along with strategic and commercial updates.
"2025 was our strongest commercial year on record — 85 new agreements signed and contracted and late stage ARR contracts representing $12.9 million are expected to begin converting to revenue in 2026 and 2027. Reported revenue declined due to a single legacy client loss from the Twill acquisition — a scope change and nonrenewal, but the fourth quarter already returned to sequential growth. With a pipeline of commercial opportunities expanded to $122 million, we enter 2026 with strong near-term visibility and what we believe is a compelling foundation for sustained high growth," stated Dario's CEO, Erez Raphael."As for AI, Dario owns the entire vertical value chain down to the clinical data itself – and the value of AI is determined entirely by the quality of data it runs on. Our platform spans proprietary hardware that generates continuous physiological data, intelligent personalized interventions, coaching, and analytics — all built on 13 billion real-world data points across longitudinal member journeys. We do not license our data, rent our AI, or depend on third-party content. We believe that ownership is a structural competitive advantage that strengthens with every new member and every new data point."Commercial Momentum Continues as Dario Delivers Savings to Payers and Employers & Improved Health Outcomes to Members:In 2025 Dario signed 85 new contracts, many of which are starting to contribute revenue in 2026, with average client and contract size increasing 2X-10X compared to its historical average, more than doubling its new account target for the year. The majority of new contracts were for Dario's multi-condition platforms — the primary driver behind the 2x–10x expansion in average contract size.Pipeline of commercial opportunities increased to $122 million. The pipeline is comprised of 230 opportunities, primarily business-to-business-to-consumer ("B2B2C") contracts. More than 70% of pipeline opportunities are multi-condition, reflecting materially higher average contract values per opportunity compared to single-condition point solutions.Dario delivers more clinical proof of ROI than any other digital health company with 100+ scientific studies including peer-reviewed journal publications and conference abstracts, demonstrating the Company's leadership in delivering rigorously validated outcomes for employers, health plans and their members.The launch of AI-driven DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further reinforcing Dario's position as a leader in digital health.Dario's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans in one of the fastest growing expense centers for payers."We are seeing strong engagement from large payers and employers across the U.S., all focused on a single priority — reducing healthcare costs while improving member outcomes. As healthcare expenses continue to rise, digital health has become an important strategic lever for driving behavior change and delivering measurable clinical and financial results," said Steven Nelson, Dario's President and Chief Commercial Officer."What is driving growth and what makes our model structurally different is that it compounds at two levels simultaneously. At the client level, channel partnerships give us access to millions of covered lives through a single commercial relationship, eliminating the account-by-account selling that we believe limits many competitors and reduces our cost of acquisition. At the member level, our multi-condition platform means a far greater share of each client's population qualifies for Dario — resulting in more members reached, more members enrolled, and potentially more revenue generated within the same account. One expands how many accounts we can reach, while the other expands how many members we can serve within each account. That is the compounding.""Through channel partnerships with organizations such as Solera, Amwell, and leading national health plans including Aetna, we now have access to approximately 116 million covered lives. As these ecosystems expand, we anticipate that they will allow Dario to reach significantly larger populations without proportional increases in sales infrastructure.""Quarter-over-Quarter Revenue Growth and Continued Operating Expense (OpEx) Improvement:Fourth quarter revenues grew quarter-over-quarter to $5.2 million from $5.0 million in the third quarter of 2025.Gross margin increased year-over-year to 57% in 2025, from 49% in 2024.Cash and short-term deposit balance of $26 million with reduced operating expenses, growing ARR, and robust B2B2C margins.Net cash used in operating activities declined from $38.6 million in 2024 to $25.9 million in 2025, representing a 33% reduction.Operating expenses continue to decrease — fourth quarter 2025 total operating expense declined 28% to $11.4 million year-over-year and declined 9% quarter-over-quarter; full year 2025 total operating expense declined by 31% to $49.3 million compared to 2024.Continued narrowing in operating loss — fourth quarter total operating loss declined 27% to $8.6 million year-over-year and 10% quarter-over-quarter; full year 2025 operating loss declined by 37% to $36.7 million compared to 2024.Non–GAAP operating loss is expected to decrease by approximately 30% in 2026, targeting towards cashflow breakeven by mid-2027 based on large scale channel partner contracted and near-closing ARR, increasing commercial pipeline and reductions in operating expenses."Our financial trending continues to improve as operating expenses decline and our core B2B2C ARR business is contributing approximately 80% gross margins, on a non-GAAP basis" stated Chen Franco Yehuda, Dario's Chief Financial Officer. "In fact, the fourth quarter of 2025 delivered the lowest operating expense run-rate, on both a GAAP and non-GAAP basis, since the Twill acquisition. With disciplined financial controls, ongoing operating efficiencies and AI utilization, we reduced net cash used in operations, which declined by 33% year over year." Financial Results for the Three Months Ended December 31, 2025Revenue for the three months ended December 31, 2025 was $5.2 million, compared to $7.6 million, for the three months ended December 31, 2024, and $5.0 million for the three months ended September 30, 2025. The year-over-year decrease was primarily due to Dario's transition away from one-time and non-recurring revenues to its focus on building ARR revenues from its core B2B2C business and a significant scope change with a large national health plan client that came with the Twill acquisition and was not renewed in the beginning of 2025. The quarter-over-quarter increase in revenues is the result of an acceleration in new ARR revenue contracts from large employers and health plans, in line with Dario's growth strategy.Gross profit for the three months ended December 31, 2025 was $2.8 million, compared to gross profit of $4.2 million for the three months ended December 31, 2024, and gross profit of $3.0 million for the three months ended September 30, 2025. The reason for the decrease as compared to the three months ended December 31, 2024 resulted mainly from the change in revenue, partially offset by lower amortization of technology expenses record in the cost of revenues. The decrease as compared to the three months ended September 30, 2025 was primarily due to higher costs recorded in the cost of revenues. Gross profit as a percentage of revenue was 54% in the three months ended December 31, 2025, compared to 55% in the three months ended December 31, 2024, and 60% in the three months ended September 30, 2025.Non-GAAP gross profit, excluding $0.2 million of amortization expenses related to stock-based compensation and depreciation was $3.0 million, or 57% of revenues, for the three months ended December 31, 2025, compared to non-GAAP gross profit of $5.5 million, or 72% of revenues, for the three months ended December 31, 2024, and a non-GAAP gross profit of $3.2 million, or 64% of revenues, for the three months ended September 30, 2025. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Total operating expenses for the three months ended December 31, 2025, were $11.4 million compared to $15.9 million for the three months ended December 31, 2024, and $12.5 million for the three months ended September 30, 2025 a decrease of $4.5 million, or 28%, compared to the three months ended December 31, 2024, and a decrease of $1.1 million, or 9%, compared to the three months ended September 30, 2025. The year-over-year decrease in operating expenses resulted mainly from post-merger integration activities and increased operational efficiency. The quarter-over-quarter decrease was driven by continued realization of these operational efficiencies and an approximately $0.3 million Coronavirus Aid, Relief, and Economic Security (CARES) Act payment received in the three months ended December 31, 2025 which was offset from operating expenses.Non-GAAP operating expenses (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended December 31, 2025, were $9.0 million compared to $12.4 million for the three months ended December 31, 2024, and $9.2 million for the three months ended September 30, 2025, representing a decrease of 28% and 2%, respectively.Operating loss for the three months ended December 31, 2025, was $8.6 million, a decrease of $3.1 million, or 27%, compared to $11.7 million for the three months ended December 31, 2024, and a decrease of $0.9 million or 10% from $9.5 million for the three months ended September 30, 2025. The decrease in operating loss year-over-year and quarter-over-quarter, was mainly due to an increase in operational efficiencies and post-merger integration activities.Non-GAAP operating loss (excluding stock-based compensation, acquisition-related expenses, and depreciation and amortization) for the three months ended December 31, 2025 was $6.0 million, representing a 14% decrease compared to a non-GAAP operating loss of $6.9 million for the three months ended December 31, 2024, and remained flat compared to a non-GAAP operating loss of $6.0 million for the three months ended September 30, 2025.Net loss was $9.0 million for the three months ended December 31, 2025, a narrowing of $0.6 million or 6% compared to a net loss of $9.6 million for the three months ended December 31, 2024, and a decline of $1.5 million or 14% from $10.5 million for three months ended September 30, 2025. Net loss narrowed year-over-year, driven by a reduction in total operating expenses, partially offset by a financial income, primarily due to revaluation of warrants recognized in the prior-year quarter. The quarter-over-quarter improvement driven mainly by lower operating expenses.Non-GAAP net loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended December 31, 2025 increased by 32% to $6.5 million compared to a non-GAAP net loss of $4.9 million for the three months ended December 31, 2024, and narrowed by 7% quarter-over-quarter from a non-GAAP net loss of $7.0 million in the three months ended September 30, 2025.A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Financial Results for the Year Ended December 31, 2025Revenues for the year ended December 31, 2025 were $22.4 million, compared to $27.0 million for the year ended December 31, 2024, primarily due to Dario's transition away from one-time and non-recurring revenues to its focus on building ARR revenues from its core B2B2C business and a significant scope change with a large national health plan client that came through the Twill acquisition and was not renewed in the beginning of 2025, partially offset by new ARR.Gross profit for the year ended December 31, 2025, was $12.7 million, compared to gross profit of $13.3 million for the year ended December 31, 2024. Gross profit as a percentage of revenues increased year-over-year to 57% in the year ended December 31, 2025, from 49% in the year ended December 31, 2024. The decrease in gross profit compared to the year ended December 31, 2024 resulted mainly from the decline in revenues, partially offset by lower technology amortization and other costs included in cost of revenues, which contributed to the improvement in gross profit as a percentage of revenues year-over-year.Non-GAAP gross profit, excluding $1.7 million of amortization expenses related to stock-based compensation and depreciation, was $14.4million, or 64% of revenues, for the year ended December 31, 2025, compared to non-GAAP gross profit of $18.4 million, or 68% of revenues, for the year ended December 31, 2024. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Total operating expenses for the year ended December 31, 2025, were $49.3 million compared to $71.0 million for the year ended December 31, 2024, a decrease of $21.7 million, or 31%. The decrease in operating expenses compared to the year ended December 31, 2024, resulted mainly from increased operational efficiencies and post-merger integration activities.Non-GAAP operating expenses (excluding stock-based compensation, acquisition-related expenses, depreciation and amortization expenses) for the year ended December 31, 2025, were $38.6 million compared to $52.2 million for the year ended December 31, 2024, representing a decrease of $13.6 million.Operating loss for the year ended December 31, 2025, was $36.7 million, a decrease of $21.0 million, or 37%, compared to $57.7 million for the year ended December 31, 2024. The decrease in operating loss compared to the year ended December 31, 2024, was mainly due to an increase in operational efficiencies and post-merger integration activities.Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the year ended December 31, 2025 was $24.1 million representing a decrease of 29%, compared to a non-GAAP operating loss of $33.8 million in the year ended December 31, 2024. Net loss was $41.7 million for the year ended December 31, 2025, a decline of 2% or $1.0 million compared to a net loss of $42.7 million for the year ended December 31, 2024.Non-GAAP net loss (excluding stock-based compensation, acquisition-related expenses, and depreciation and amortization) for the year ended December 31, 2025 was $29.2 million, compared to $18.8 million for the year ended December 31, 2024. The increase in non-GAAP net loss was primarily due to the revaluation of pre-funded warrants, partially offset by a decrease in operating loss.A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Conference Call DetailsDate: Thursday, March 19th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)Call me™: https://emportal.ink/4sksMwGParticipants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1748263&tp_key=02d7c540f8Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Thursday, April 2nd, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1191893.About DarioHealth Corp. (NASDAQ: DRIO)DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that agreements entered into in 2025 will provide recurring revenue in 2026 and 2027, positioning the Company for a high-growth trajectory; its belief that increased demand for the Company's MSK product in the B2C market will result in expansion in international markets; its belief that the Company's model will provide compounding growth resulting in an expected increase in account outreach and growth, member enrollment and resulting revenue, increased through client collaborations and member enrollment; its belief that the Company's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans; its belief that the Company's channel partnerships will expand and its expectation that such expansion will allow the Company to reach significantly larger populations without proportional increases in sales infrastructure; and its expectation that the Company will reduce its operating loss by 30% and reach cashflow breakeven by mid-2027. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.Non-GAAP Financial MeasuresWe have provided financial information in this release that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition-related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, depreciation and impairment expense, amortization of acquired technology and brand, financial (income) expenses, net, income tax, and acquisition costs. We believe these measures provide useful information to management and investors for analysis of our operating results. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETS U.S. dollars in thousands
December 31,
December 31,
2025
2024ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$21,803
$27,764Short-term bank deposits
4,214
697Short-term restricted bank deposits
229
175Trade receivables, net
2,144
4,804Inventories
4,316
4,753Other accounts receivable and prepaid expenses
2,361
2,336
Total current assets
35,067
40,529
NON-CURRENT ASSETS:
Deposits
80
79Operating lease right of use assets
717
1,065Long-term assets
304
313Property and equipment, net
549
709Intangible assets, net
15,931
18,762Goodwill
57,427
57,427
Total non-current assets
75,008
78,355
Total assets
$110,075
$118,884 DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (except stock and per share data)
December 31,
December 31,
2025
2024LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables
$2,928
$3,045Deferred revenues
714
1,583Operating lease liabilities
430
504Other accounts payable and accrued expenses
5,251
6,052Current maturity of long-term loan
—
5,451
Total current liabilities
9,323
16,635
NON-CURRENT LIABILITIES
Operating lease liabilities
571
765Long-term loan
30,747
23,472Warrant liability
1,466
5,968Other long-term liabilities
46
25
Total non-current liabilities
32,830
30,230
STOCKHOLDERS' EQUITY
Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued and
outstanding: 6,905,948 and 1,919,422 shares on December 31, 2025 and
December 31, 2024, respectively
4
4Preferred stock of $0.0001 par value - authorized: 5,000,000 shares; issued and
outstanding: 0 and 49,585 shares on December 31, 2025 and December 31, 2024,
respectively
*) -
*) -Additional paid-in capital
519,996
462,358Accumulated deficit
(452,078)
(390,343)
Total stockholders' equity
67,922
72,019
Total liabilities and stockholders' equity
$110,075
$118,884 *) Represents an amount lower than $1. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands (except stock and per share data)
Year ended
December 31,
2025
2024Revenues:
Services
$14,929
$20,197Consumer hardware
7,430
6,843Total revenues
22,359
27,040
Cost of revenues:
Services
2,900
3,606Consumer hardware
5,124
5,139Amortization of acquired intangible assets
1,670
5,028Total cost of revenues
9,694
13,773
Gross profit
12,665
13,267
Operating expenses:
Research and development
$13,791
$24,179Sales and marketing
20,338
26,350General and administrative
15,191
20,482
Total operating expenses
49,320
71,011
Operating loss
36,655
57,744
Interest expenses
3,020
—Other financial expenses (income), net
1,934
(13,145)
Total financial expenses (income), net
4,954
(13,145)
Loss before taxes
41,609
44,599
Income taxes (benefit)
105
(1,852)
Net loss
$41,714
$42,747
Deemed dividend (contribution)
$20,021
$(1,765)
Net loss attributable to common shareholders
$61,735
$40,982
Net loss per share:
Basic and diluted loss per share of common stock
$10.12
$12.27Weighted average number of common stock used in computing
basic and diluted net loss per share**
3,982,956
2,451,971 DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSU.S. dollars in thousands
Year ended
December 31,
2025
2024Cash flows from operating activities:
Net loss
$(41,714)
$(42,747)Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation
9,365
15,796Change in operating lease right of use assets
421
907Amortization of acquired intangible assets
2,831
6,100Changes in operating assets and liabilities, net of effects of businesses acquired:
Depreciation and impairment
307
1,327Decrease in trade receivables, net
2,660
1,680Increase in other accounts receivable, prepaid expense and long-term assets
(16)
(80)Decrease in inventories
437
308Decrease in trade payables
(122)
(496)Decrease in other accounts payable and accrued expenses
(780)
(3,483)Decrease in deferred revenues
(869)
(156)Change in operating lease liabilities
(341)
(1,150)Change in fair value of warrant liability
(1,681)
(16,504)Accrued interest on short term bank deposits
(14)
—Non-cash financial expenses
2,933
516Other
642
(580)
Net cash used in operating activities
(25,941)
(38,562)
Cash flows from investing activities:
Purchase of property and equipment, net
(142)
(138)Investments in short-term bank deposits
(4,200)
—Payments for business acquisitions, net of cash acquired
—
(8,796)
Net cash used in investing activities
(4,342)
(8,934)
Cash flows from financing activities:
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs
17,374
—Proceeds from issuance of preferred stock, net of issuance costs
6,754
38,531Proceeds from borrowings on credit agreement, net
31,700
—Repayment of long-term loan
(31,515)
—
Net cash provided by financing activities
24,313
38,531
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents
(5,970)
(8,965)Effect of exchange rate differences on cash, cash equivalents and restricted cash and
cash equivalents
9
(68)Cash, cash equivalents and restricted cash and cash equivalents at beginning of period
27,764
36,797Cash, cash equivalents and restricted cash and cash equivalents at end of period
$21,803
$27,764Supplemental disclosure of cash flow information:
Cash paid during the period for interest on long-term loan
$3,493
$3,927Non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities
$73
$428Purchase of property and equipment on credit
5
—Exercise of pre-funded warrants to common stock upon acquisition
$2,821
$2,225 Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended December 31, 2025
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$2,427
(4)
(184)
2,239Gross Profit
2,804
4
184
2,992
Research and development
2,634
(267)
(31)
2,336Sales and Marketing
4,630
(300)
(308)
4,022General and Administrative
4,102
(1,467)
(10)
2,625Total Operating Expenses
11,366
(2,034)
(349)
8,983Operating Loss$(8,562)
2,038
533
(5,991)Financing expenses
386
-
-
386Income Tax
83
-
-
83Net Loss$(9,031)
2,038
538
(6,460) Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended December 31, 2024
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$3,402
(8)
(1,302)
2,092Gross Profit
4,202
(8)
1,302
5,512
Research and development
5,281
(985)
(51)
4,245Sales and Marketing
5,575
(536)
(325)
4,714General and Administrative
5,014
(1,061)
(474)
3,479Total Operating Expenses
15,870
(2,582)
(850)
12,438Operating Loss$(11,668)
2,590
2,152
(6,926)Financing expenses
(2,191)
-
-
(2,191)Income Tax
155
-
-
155Net Loss$(9,632)
2,590
2,152
(4,890) Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Twelve months ended December 31, 2025
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$9,694
(26)
(1,713)
7,955Gross Profit
12,665
26
1,713
14,404
Research and development
(13,791)
(1,623)
(135)
(12,033)Sales and Marketing
(20,338)
(2,253)
(1,234)
(16,851)General and Administrative
(15,191)
(5,463)
(56)
(9,672)Total Operating Expenses
(49,320)
(9,339)
(1,425)
(38,556)Operating Loss$(36,655)
9,365
3,138
(24,152)Financing expenses
4,954
-
-
4,954Income Tax
105
-
-
105Net Loss$(41,714)
9,365
3,138
(29,211) Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Twelve months ended December 31, 2024
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon -GAAPCost of Revenues$13,773
(13)
(5,086)
8,674Gross Profit
13,267
13
5,086
18,366
Research and development
24,179
(3,296)
(238)
20,645Sales and Marketing
26,350
(4,890)
(1,183)
20,277General and Administrative
20,482
(7,597)
(1,649)
11,236Total Operating Expenses
71,011
(15,783)
(3,070)
52,158Operating Loss$(57,744)
15,796
8,156
(33,792)Financing expenses
(13,145)
-
-
(13,145)Income Tax
(1,852)
-
-
(1,852)Net Loss$(42,747)
15,796
8,156
(18,795) DarioHealth Corporate ContactZoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.comDarioHealth Investor Relations ContactMichael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310Logo - https://mma.prnewswire.com/media/2866807/5869548/Dario_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-302718542.htmlSOURCE DarioHealth Corp.
Original: DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Jackthehorse1926
2月前
ipo_dude
2年前
rtrstock
5年前
whytestocks
6年前
メールアドレスで登録
